Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,422 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study.
Janssen HLA, Lim YS, Lampertico P, Heo J, Chen CY, Fournier C, Tsang TYO, Bae H, Chen CH, Coffin CS, Ahn SH, Trinh H, Flaherty JF, Abramov F, Zhao Y, Liu Y, Lau A, German P, Chuang WL, Agarwal K, Gane E. Janssen HLA, et al. Among authors: agarwal k. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):718-733. doi: 10.1016/S2468-1253(24)00096-7. Epub 2024 Jun 17. Lancet Gastroenterol Hepatol. 2024. PMID: 38901444 Clinical Trial.
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Reau N, et al. Among authors: agarwal k. Hepatology. 2018 Oct;68(4):1298-1307. doi: 10.1002/hep.30046. Epub 2018 Jul 25. Hepatology. 2018. PMID: 29672891 Free PMC article. Clinical Trial.
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
Flamm S, Mutimer D, Asatryan A, Wang S, Rockstroh J, Horsmans Y, Kwo PY, Weiland O, Villa E, Heo J, Gane E, Ryder SD, Welzel TM, Ruane PJ, Agarwal K, Ng TI, Xue Z, Lovell SS, Krishnan P, Kopecky-Bromberg S, Trinh R, Mensa FJ, Wyles DL. Flamm S, et al. Among authors: agarwal k. J Viral Hepat. 2019 Mar;26(3):337-349. doi: 10.1111/jvh.13038. Epub 2018 Dec 11. J Viral Hepat. 2019. PMID: 30421537 Free PMC article. Clinical Trial.
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z; STELLAR-3; STELLAR-4 Investigators. Harrison SA, et al. J Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6. J Hepatol. 2020. PMID: 32147362 Clinical Trial.
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE).
Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B; CREATE Study Group. Sonneveld MJ, et al. Among authors: agarwal k. Clin Gastroenterol Hepatol. 2022 Apr;20(4):e784-e793. doi: 10.1016/j.cgh.2020.12.005. Epub 2020 Dec 10. Clin Gastroenterol Hepatol. 2022. PMID: 33309804 Free article.
Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis.
Brunetto MR, Carey I, Maasoumy B, Marcos-Fosch C, Boonstra A, Caviglia GP, Loglio A, Cavallone D, Scholtes C, Ricco G, Smedile A, Riveiro-Barciela M, van Bömmel F, van der Eijk A, Zoulim F, Berg T, Cornberg M, Lampertico P, Agarwal K, Buti M. Brunetto MR, et al. Among authors: agarwal k. Aliment Pharmacol Ther. 2021 Mar;53(6):733-744. doi: 10.1111/apt.16258. Epub 2021 Jan 19. Aliment Pharmacol Ther. 2021. PMID: 33465257 Free article.
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.
Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B; CREATE study group. Sonneveld MJ, et al. Among authors: agarwal k. J Hepatol. 2022 May;76(5):1042-1050. doi: 10.1016/j.jhep.2022.01.007. Epub 2022 Jan 29. J Hepatol. 2022. PMID: 35092743 Free article.
1,422 results